M. Luisa Paccagnella

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

David Olmos, Sophie Postel‐Vinay, L Rhoda Molife et al. · The Lancet Oncology · 2009 · 339 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +16

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

Paul Haluska, F. Worden, David Olmos et al. · Cancer Chemotherapy and Pharmacology · 2009 · 191 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +11

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

Martha Q. Lacy, Melissa Alsina, Rafaël Fonseca et al. · Journal of Clinical Oncology · 2008 · 160 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO‐VATE

Elias Jabbour, Daniel J. DeAngelo, Matthias Stelljes et al. · Cancer · 2018 · 58 citations · Full text

Medicine, Oncology, Pharmacotherapy +13